Medical treatment of orthotopic glioblastoma with transferrin conjugated nanoparticles encapsulating zoledronic acid

Manuela Porru, Silvia Zappavigna, Giuseppina Salzano, Amalia Luce, Antonella Stoppacciaro, Maria Luisa Balestrieri, Simona Artuso, Sara Lusa, Giuseppe De Rosa, Carlo Leonetti, Michele Caraglia

Research output: Contribution to journalArticle

Abstract

Glioblastomas are highly aggressive adult brain tumors with poor clinical outcome. In the central nervous system (CNS) the blood-brain barrier (BBB) is the most important limiting factor for both development of new drugs and drug delivery. Here, we propose a new strategy to treat glioblastoma based on transferrin (Tf)- targeted self-assembled nanoparticles (NPs) incorporating zoledronic acid (ZOL) (NPs-ZOL-Tf). NPs-ZOL-Tf have been assessed on the glioblastoma cell line U373MGLUC that showed a refractoriness in vitro to temozolomide (TMZ) and fotemustine (FTM). NPs-ZOL-Tf treatment resulted in higher in vitro cytotoxic activity than free ZOL. However, the potentiation of anti-proliferative activity of NPs-ZOL-Tf was superimposable to that one induced by NPs-ZOL (not armed with Tf). On the other hand, NPs-ZOL-Tf showed a higher antitumor efficacy if compared with that one caused by NPs-ZOL in immunosuppressed mice intramuscularly bearing U373MG-LUC xenografts, inducing a significant tumor weight inhibition (TWI). The experiments performed on mice with intracranial U373MG-LUC xenografts confirmed the efficacy of NPs-ZOL-Tf. These effects were paralleled by a higher intratumour localization of fluorescently-labeled-NPs-Tf both in intramuscular and intracranial xenografts. In conclusion, our results demonstrate that the encapsulation of ZOL increases the antitumor efficacy of this drug in glioblastoma through the acquisition of ability to cross the BBB.

Original languageEnglish
Pages (from-to)10446-10459
Number of pages14
JournalOncotarget
Volume5
Issue number21
Publication statusPublished - 2014

Fingerprint

zoledronic acid
Glioblastoma
Transferrin
Nanoparticles
Heterografts
temozolomide
fotemustine
Blood-Brain Barrier

Keywords

  • Calcium phosphate self-assembly nanoparticles
  • Delivery
  • Glioblastoma
  • Intracranial xenografts
  • Transferrin
  • Zoledronic acid

ASJC Scopus subject areas

  • Oncology

Cite this

Porru, M., Zappavigna, S., Salzano, G., Luce, A., Stoppacciaro, A., Balestrieri, M. L., ... Caraglia, M. (2014). Medical treatment of orthotopic glioblastoma with transferrin conjugated nanoparticles encapsulating zoledronic acid. Oncotarget, 5(21), 10446-10459.

Medical treatment of orthotopic glioblastoma with transferrin conjugated nanoparticles encapsulating zoledronic acid. / Porru, Manuela; Zappavigna, Silvia; Salzano, Giuseppina; Luce, Amalia; Stoppacciaro, Antonella; Balestrieri, Maria Luisa; Artuso, Simona; Lusa, Sara; De Rosa, Giuseppe; Leonetti, Carlo; Caraglia, Michele.

In: Oncotarget, Vol. 5, No. 21, 2014, p. 10446-10459.

Research output: Contribution to journalArticle

Porru, M, Zappavigna, S, Salzano, G, Luce, A, Stoppacciaro, A, Balestrieri, ML, Artuso, S, Lusa, S, De Rosa, G, Leonetti, C & Caraglia, M 2014, 'Medical treatment of orthotopic glioblastoma with transferrin conjugated nanoparticles encapsulating zoledronic acid', Oncotarget, vol. 5, no. 21, pp. 10446-10459.
Porru M, Zappavigna S, Salzano G, Luce A, Stoppacciaro A, Balestrieri ML et al. Medical treatment of orthotopic glioblastoma with transferrin conjugated nanoparticles encapsulating zoledronic acid. Oncotarget. 2014;5(21):10446-10459.
Porru, Manuela ; Zappavigna, Silvia ; Salzano, Giuseppina ; Luce, Amalia ; Stoppacciaro, Antonella ; Balestrieri, Maria Luisa ; Artuso, Simona ; Lusa, Sara ; De Rosa, Giuseppe ; Leonetti, Carlo ; Caraglia, Michele. / Medical treatment of orthotopic glioblastoma with transferrin conjugated nanoparticles encapsulating zoledronic acid. In: Oncotarget. 2014 ; Vol. 5, No. 21. pp. 10446-10459.
@article{8fbd8618023a4337b3d1eed1d051b69d,
title = "Medical treatment of orthotopic glioblastoma with transferrin conjugated nanoparticles encapsulating zoledronic acid",
abstract = "Glioblastomas are highly aggressive adult brain tumors with poor clinical outcome. In the central nervous system (CNS) the blood-brain barrier (BBB) is the most important limiting factor for both development of new drugs and drug delivery. Here, we propose a new strategy to treat glioblastoma based on transferrin (Tf)- targeted self-assembled nanoparticles (NPs) incorporating zoledronic acid (ZOL) (NPs-ZOL-Tf). NPs-ZOL-Tf have been assessed on the glioblastoma cell line U373MGLUC that showed a refractoriness in vitro to temozolomide (TMZ) and fotemustine (FTM). NPs-ZOL-Tf treatment resulted in higher in vitro cytotoxic activity than free ZOL. However, the potentiation of anti-proliferative activity of NPs-ZOL-Tf was superimposable to that one induced by NPs-ZOL (not armed with Tf). On the other hand, NPs-ZOL-Tf showed a higher antitumor efficacy if compared with that one caused by NPs-ZOL in immunosuppressed mice intramuscularly bearing U373MG-LUC xenografts, inducing a significant tumor weight inhibition (TWI). The experiments performed on mice with intracranial U373MG-LUC xenografts confirmed the efficacy of NPs-ZOL-Tf. These effects were paralleled by a higher intratumour localization of fluorescently-labeled-NPs-Tf both in intramuscular and intracranial xenografts. In conclusion, our results demonstrate that the encapsulation of ZOL increases the antitumor efficacy of this drug in glioblastoma through the acquisition of ability to cross the BBB.",
keywords = "Calcium phosphate self-assembly nanoparticles, Delivery, Glioblastoma, Intracranial xenografts, Transferrin, Zoledronic acid",
author = "Manuela Porru and Silvia Zappavigna and Giuseppina Salzano and Amalia Luce and Antonella Stoppacciaro and Balestrieri, {Maria Luisa} and Simona Artuso and Sara Lusa and {De Rosa}, Giuseppe and Carlo Leonetti and Michele Caraglia",
year = "2014",
language = "English",
volume = "5",
pages = "10446--10459",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "21",

}

TY - JOUR

T1 - Medical treatment of orthotopic glioblastoma with transferrin conjugated nanoparticles encapsulating zoledronic acid

AU - Porru, Manuela

AU - Zappavigna, Silvia

AU - Salzano, Giuseppina

AU - Luce, Amalia

AU - Stoppacciaro, Antonella

AU - Balestrieri, Maria Luisa

AU - Artuso, Simona

AU - Lusa, Sara

AU - De Rosa, Giuseppe

AU - Leonetti, Carlo

AU - Caraglia, Michele

PY - 2014

Y1 - 2014

N2 - Glioblastomas are highly aggressive adult brain tumors with poor clinical outcome. In the central nervous system (CNS) the blood-brain barrier (BBB) is the most important limiting factor for both development of new drugs and drug delivery. Here, we propose a new strategy to treat glioblastoma based on transferrin (Tf)- targeted self-assembled nanoparticles (NPs) incorporating zoledronic acid (ZOL) (NPs-ZOL-Tf). NPs-ZOL-Tf have been assessed on the glioblastoma cell line U373MGLUC that showed a refractoriness in vitro to temozolomide (TMZ) and fotemustine (FTM). NPs-ZOL-Tf treatment resulted in higher in vitro cytotoxic activity than free ZOL. However, the potentiation of anti-proliferative activity of NPs-ZOL-Tf was superimposable to that one induced by NPs-ZOL (not armed with Tf). On the other hand, NPs-ZOL-Tf showed a higher antitumor efficacy if compared with that one caused by NPs-ZOL in immunosuppressed mice intramuscularly bearing U373MG-LUC xenografts, inducing a significant tumor weight inhibition (TWI). The experiments performed on mice with intracranial U373MG-LUC xenografts confirmed the efficacy of NPs-ZOL-Tf. These effects were paralleled by a higher intratumour localization of fluorescently-labeled-NPs-Tf both in intramuscular and intracranial xenografts. In conclusion, our results demonstrate that the encapsulation of ZOL increases the antitumor efficacy of this drug in glioblastoma through the acquisition of ability to cross the BBB.

AB - Glioblastomas are highly aggressive adult brain tumors with poor clinical outcome. In the central nervous system (CNS) the blood-brain barrier (BBB) is the most important limiting factor for both development of new drugs and drug delivery. Here, we propose a new strategy to treat glioblastoma based on transferrin (Tf)- targeted self-assembled nanoparticles (NPs) incorporating zoledronic acid (ZOL) (NPs-ZOL-Tf). NPs-ZOL-Tf have been assessed on the glioblastoma cell line U373MGLUC that showed a refractoriness in vitro to temozolomide (TMZ) and fotemustine (FTM). NPs-ZOL-Tf treatment resulted in higher in vitro cytotoxic activity than free ZOL. However, the potentiation of anti-proliferative activity of NPs-ZOL-Tf was superimposable to that one induced by NPs-ZOL (not armed with Tf). On the other hand, NPs-ZOL-Tf showed a higher antitumor efficacy if compared with that one caused by NPs-ZOL in immunosuppressed mice intramuscularly bearing U373MG-LUC xenografts, inducing a significant tumor weight inhibition (TWI). The experiments performed on mice with intracranial U373MG-LUC xenografts confirmed the efficacy of NPs-ZOL-Tf. These effects were paralleled by a higher intratumour localization of fluorescently-labeled-NPs-Tf both in intramuscular and intracranial xenografts. In conclusion, our results demonstrate that the encapsulation of ZOL increases the antitumor efficacy of this drug in glioblastoma through the acquisition of ability to cross the BBB.

KW - Calcium phosphate self-assembly nanoparticles

KW - Delivery

KW - Glioblastoma

KW - Intracranial xenografts

KW - Transferrin

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84916899852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916899852&partnerID=8YFLogxK

M3 - Article

C2 - 25431953

AN - SCOPUS:84916899852

VL - 5

SP - 10446

EP - 10459

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 21

ER -